Clozapine enhances disruption of prepulse inhibition after sub-chronic dizocilpine- or phencyclidine-treatment in Wistar rats

T-817MA, a novel neurotrophic compound, ameliorates phencyclidine-induced disruption of sensorimotor gating

“…Vehicle/water group, n=10; vehicle/T-817MA group, n=11; PCP/water group, n= 18; PCP/T-817MA group, n=13. ***p<0.001; main effects of treatment (PCP vs. vehicle) Most previous studies investigating the effect of chronic treatment with PCP on PPI used treatment periods up to 3 weeks (e.g., Martinez et al 1999;Schwabe et al 2005;Tenn et al 2005). PPI disruption on termination of intermittent treatment with PCP for 1 month, as demonstrated in the present study, was similar to the results of previous studies using a shorter treatment period (e.g., Martinez et al 1999;Schwabe et al 2005;Tenn et al 2005).…”

“…***p<0.001; main effects of treatment (PCP vs. vehicle) Most previous studies investigating the effect of chronic treatment with PCP on PPI used treatment periods up to 3 weeks (e.g., Martinez et al 1999;Schwabe et al 2005;Tenn et al 2005). PPI disruption on termination of intermittent treatment with PCP for 1 month, as demonstrated in the present study, was similar to the results of previous studies using a shorter treatment period (e.g., Martinez et al 1999;Schwabe et al 2005;Tenn et al 2005). On the other hand, a residual effect of chronic intermittent treatment with PCP on PPI was noted 2 days after the last injection of PCP in the present study, whereas the above previous studies did not show such an effect.…”

“…On the other hand, a residual effect of chronic intermittent treatment with PCP on PPI was noted 2 days after the last injection of PCP in the present study, whereas the above previous studies did not show such an effect. Martinez et al (1999) and Schwabe et al (2005) treated rats with PCP for 14 and 11 days, respectively, whereas Tenn et al (2005) did it for 3 weeks. Therefore, we assumed that the discrepancy regarding the long-lasting effect of PCP on PPI was due to the relatively lengthy period of PCP administration (i.e., 1 month) in the current study.…”

“…PPI is disrupted in neuropsychiatric disorders, including schizophrenia (Braff et al 1978;Braff and Geyer 1990;Swerdlow et al 1994). In animals, a variety of psychostimulants, such as dopamine agonists (amphetamine, apomorphine; Mansbach et al 1988;Swerdlow et al 1986;Geyer et al 1999;Martinez et al 2000) and noncompetitive antagonists at NMDA receptors (phencyclidine, MK-801, ketamine; Mansbach and Geyer 1989;Geyer 1995, 1997;Bubenikova et al 2005;Geyer et al 1999;Martinez et al 2000;Myers et al 2005;Pietraszek et al 2005;Pouzet et al 2005;Schwabe et al 2005) have been shown to disrupt PPI. In particular, animal models using noncompetitive NMDA antagonists are considered to be most reliable for producing a range of abnormal behaviors related with symptoms of schizophrenia, including PPI deficits.…”

Long-term effects of developmental PCP administration on sensorimotor gating in male and female rats

“…The noncompetitive antagonists PCP (phencyclidine) and MK-801 (dizocilpine) have been shown to reliably disrupt PPI Schwabe et al 2005). Furthermore, neonatal treatment with MK-801 may reduce the normal systematic effect of prepulse levels on PPI later in development (Beninger et al 2002).…”